Kam Sung Chul, Choi See Min, Yoon Sol, Choi Jae Hui, Lee Seong Hyun, Hwa Jeong Seok, Chung Ky Hyun, Hyun Jae Seog
Department of Urology, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
Korean J Urol. 2014 Nov;55(11):732-6. doi: 10.4111/kju.2014.55.11.732. Epub 2014 Nov 10.
Transrectal ultrasound (TRUS)-guided biopsy of the prostate is usually safe. However, some patients are hospitalized owing to complications from TRUS biopsy. We identified the risk factors for complications and effective preventive measures for treating complications after TRUS biopsy.
Medical records and radiological images of 1,083 patients who underwent TRUS biopsy of the prostate over 10 years in Gyeongsang National University Hospital were examined retrospectively to investigate the correlation between complications after TRUS biopsy and preventive antibiotics, prebiopsy enema, number of biopsy cores, and pathological findings.
Complications occurred in 69 patients (6.4%). The complication rates of the 1,008 patients who received antibiotics and the 75 patients who did not were 6.3% and 8.0%, respectively (p=0.469). Complication rates of the pre-biopsy enema group (n=658) and the group without prebiopsy enema (n=425) were 4.7% and 8.9%, respectively (p=0.007). Complication rates of the 6-core biopsy group (n=41) and the 12-core biopsy group (n=955) were 7.3% and 6.3%, respectively (p=0.891). Complication rates of the prostate cancer group (n=306) and the no prostate cancer group (n=713) were 6.2% and 6.6%, respectively (p=0.740).
A prebiopsy enema was associated with a reduced risk of complications after TRUS biopsy. Preventive antibiotics, number of biopsy cores, and pathological findings did not significantly influence the complication rate.
经直肠超声(TRUS)引导下的前列腺活检通常是安全的。然而,一些患者因TRUS活检的并发症而住院。我们确定了并发症的危险因素以及TRUS活检后治疗并发症的有效预防措施。
回顾性研究庆尚国立大学医院10年间接受TRUS引导下前列腺活检的1083例患者的病历和影像学资料,以探讨TRUS活检后并发症与预防性抗生素、活检前灌肠、活检芯数量及病理结果之间的相关性。
69例患者(6.4%)出现并发症。接受抗生素治疗的1008例患者和未接受抗生素治疗的75例患者的并发症发生率分别为6.3%和8.0%(p = 0.469)。活检前灌肠组(n = 658)和未进行活检前灌肠组(n = 425)的并发症发生率分别为4.7%和8.9%(p = 0.007)。6芯活检组(n = 41)和12芯活检组(n = 955)的并发症发生率分别为7.3%和6.3%(p = 0.891)。前列腺癌组(n = 306)和非前列腺癌组(n = 713)的并发症发生率分别为6.2%和6.6%(p = 0.740)。
活检前灌肠与TRUS活检后并发症风险降低相关。预防性抗生素、活检芯数量及病理结果对并发症发生率无显著影响。